A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.

Gut · 2013 · PMC3711369 · PMID 22717454

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

A slight trend of nonlinearity was observed at doses ≤1.0 mg/kg, possibly due to target-mediated clearance at lower etrolizumab serum concentrations.

also in 2,443 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.